All In Biotech

Free tool

FAERS Monitor: Zarxio

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125553 or its brand name (Zarxio, Filgrastim-Sndz). Reports on generic versions are filed under their own applications.

Reports

3,331

Serious

1,898

57% of reports

Hospitalization

676

Death reported

751

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death635
  • fatigue174
  • white blood cell count decreased169
  • diarrhoea136
  • nausea116
  • off label use95
  • hospitalisation92
  • pyrexia91
  • neutropenia86
  • platelet count decreased76
  • asthenia75
  • bone pain74
  • rash73
  • pneumonia71
  • neoplasm malignant68

Reports by year received

View as table
YearReports
20151
201656
2017123
2018263
2019372
2020532
2021706
2022379
2023337
2024270
2025171
2026121

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,828 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
white blood cell count decreasedSignal1699.98.51,341
bone painSignal748.06.4446
neoplasm malignantSignal686.45.1308
deathSignal6354.74.31,896
platelet count decreasedSignal764.53.6205
neutropeniaSignal864.03.2191
hospitalisationSignal923.83.1187
pyrexia911.71.424
fatigue1741.41.221
pneumonia711.41.17
diarrhoea1361.31.111
asthenia751.31.04
rash731.10.80
nausea1160.90.81
off label use950.70.614

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.